Raeliva review

Raeliva is a useful comparison for someone who wants a genuine month-to-month injection price alongside an explicit longer-term purchase. Its semaglutide injection is $219 a month and tirzepatide $299, with provider review, medication, shipping and continuing support described as included. The lower $150 and approximately $242 monthly equivalents require six months paid upfront. The service also offers daily dissolving tablets, but convenience is not evidence that those compounded formulations perform like approved oral medicines or injections. Our main reservations concern the identity of the particular prescriber and dispensing pharmacy, which should be established before an order, and the difference between stopping future billing and recovering money for medication already processed. The detailed refund policy makes that distinction consequential. This is an assessment of the published service, without a test prescription, patient experience or independently verified outcome claim.

The current platform is Raeliva, operated by Pacific Shores Research Group, LLC. Its own legal pages identify that business and distinguish the platform from independent medical groups, clinicians, pharmacies and laboratories. The homepage describes its patient-volume figure as a combined total across the operator’s platforms. That is a reason to distinguish a marketing audience count from evidence about this particular treatment program. A cumulative platform total is not a Raeliva-specific treatment-outcome study, and it does not establish how many current members use a particular medication or delivery route. Weight care sits alongside NAD+, sermorelin, glutathione and lower-dose programs marketed for metabolic or longevity goals. Those additional products require separate clinical justification; buying weight-management care does not establish that a broader longevity protocol would help the same person. Raeliva advertises providers and shipping across all 50 states, but each prescription still requires clinical approval and a pharmacy able to dispense the exact formulation.

Enrollment begins with an online medical intake. A licensed provider assesses the history and decides whether treatment is appropriate; the product page describes a review without a scheduled appointment as the ordinary starting process. Established patients transferring care are asked for their current medication, dose, time on treatment and supporting records. Continuing an existing dose is a clinical decision, not a checkout entitlement. The service describes ongoing clinical messaging, check-in forms before refills and a patient portal through which a refill can be requested. That means a renewal should include a fresh assessment rather than simply repeating the last vial. Ask when the next check-in opens, how quickly a clinician answers side-effect questions and what happens if the prescriber recommends delaying treatment after a payment. The injection pages describe divided shipments for longer plans. Obtain the actual shipment schedule and pharmacy beyond-use dates in writing instead of assuming six months arrives at once. For someone trying treatment for the first time, the flexibility of the monthly option should be weighed against the cash savings of prepayment. Ask whether an unused portion is refundable if the clinician later recommends stopping. The published no-contract language does not by itself answer how an already paid six-month purchase is reconciled after a clinical change.

For semaglutide injections, the three-month purchase is $500 and the six-month purchase $900. For tirzepatide injections, the corresponding totals are $800 and $1,450. Raeliva explicitly explains that the displayed monthly equivalents on these plans are arithmetic descriptions of one upfront charge. They are not installment payments. The standard monthly price is described as unchanged when the dose rises; a promotional code applies to one order and does not permanently lower renewals. Semaglutide dissolving tablets have their own $260 monthly, $550 quarterly and $1,000 six-month prices. Do not transfer an injection price to an oral plan. The platform does not bill insurance, and use of an HSA or FSA depends on the patient’s plan. The site describes subscriptions and cancellation by support email or a care-team message, with written confirmation. Its refund policy allows limited remedies before processing and for verified errors or treatment denial, but excludes completed consultations and dispensed or shipped prescriptions. No cancellation fee is advertised; that does not make an already processed supply refundable.

Every GLP-1 in the Raeliva program is described as compounded, including semaglutide and tirzepatide injections and the sublingual dissolving tablets. The site usefully says the products are not FDA-approved and distinguishes its formulations from the branded medicines used in the trials it cites. That separation should remain central when comparing testimonials, an oral alternative and a lower price. An approved swallowed tablet, a compounded tablet intended to dissolve under the tongue and an injection have different formulation questions; sharing a molecule name does not establish equal absorption, dose equivalence or expected weight loss. Ask the prescriber why the proposed preparation is appropriate for your medical needs and what evidence applies to that route. Before accepting a vial or tablet shipment, request the dispensing pharmacy’s legal name, contact information, concentration or strength, storage instructions and beyond-use date. These practical facts are more useful than interpreting a general platform promise as a guarantee of the individual medicine’s quality or suitability.